The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.
Excess weight is linked to an especially high risk of developing breast cancer in postmenopausal women with cardiovascular disease, according to research from the International Agency for Research on Cancer. The study was published in Cancer.
